Abeona Therapeutics (NASDAQ:ABEO) SVP Brendan O’malley Sells 6,727 Shares of Company Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Brendan O’malley sold 6,727 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $34,711.32. Following the sale, the senior vice president owned 421,226 shares in the company, valued at approximately $2,173,526.16. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Stock Performance

ABEO traded down $0.13 during trading on Tuesday, reaching $5.16. 1,253,359 shares of the company’s stock were exchanged, compared to its average volume of 1,359,931. Abeona Therapeutics Inc. has a fifty-two week low of $4.00 and a fifty-two week high of $7.65. The company has a quick ratio of 6.40, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $295.07 million, a P/E ratio of -4.73 and a beta of 1.33. The business has a 50 day moving average price of $6.07 and a 200 day moving average price of $5.72.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The business had revenue of $11.38 million for the quarter, compared to analysts’ expectations of $12.24 million. As a group, analysts predict that Abeona Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ABEO has been the topic of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. UBS Group reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday. HC Wainwright reissued a “buy” rating on shares of Abeona Therapeutics in a report on Friday. Weiss Ratings downgraded shares of Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Finally, Cantor Fitzgerald upped their target price on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Abeona Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently bought and sold shares of ABEO. WINTON GROUP Ltd acquired a new stake in Abeona Therapeutics during the 2nd quarter valued at $256,000. Corient Private Wealth LP bought a new stake in shares of Abeona Therapeutics during the second quarter worth $556,000. Pale Fire Capital SE increased its stake in shares of Abeona Therapeutics by 17.3% in the second quarter. Pale Fire Capital SE now owns 81,945 shares of the biopharmaceutical company’s stock valued at $506,000 after buying an additional 12,100 shares in the last quarter. Headlands Technologies LLC increased its stake in shares of Abeona Therapeutics by 97.5% in the second quarter. Headlands Technologies LLC now owns 125,090 shares of the biopharmaceutical company’s stock valued at $773,000 after buying an additional 61,745 shares in the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of Abeona Therapeutics in the second quarter valued at about $9,184,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for patients with serious and life-threatening genetic diseases. The company’s programs are designed to address conditions for which existing treatment options are limited or inadequate.

Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and chronic wounds.